Abstract: Techniques for aligning a virtual object with a physical object in an Augmented Reality (AR) or Virtual Reality (VR) application are described. An electronic peripheral includes a first inertial measurement unit (“IMU”). A head mounted display includes a second IMU. An estimated attitude for the electronic peripheral is generated using data from the first IMU. An estimated attitude for the head mounted display is generated using data from the second IMU. An orientation of a virtual object is determined based on the estimated first and second attitudes, such that the virtual object is aligned with an object in a user's physical environment when the virtual object is displayed to the user. The virtual object is displayed on the head mounted display.

Abstract: Provided herein are methods for treating and preventing PD-1-mediated resistant cancers.

Abstract: Embodiments provide for tracking location and resolving drift in Augmented Reality (AR) devices. The AR devices includes computing devices having screens on a first face and cameras on a second, opposite face to project an image onto optical arrangements for viewing by wearers of the AR devices. The AR devices map locations for real objects in the environment to a virtual environment; anchor virtual objects at anchor locations within the virtual environment; capture station keeping images of the environment from a first Field of View via the camera; determine a second, different Field of View in the environment for the wearer of the AR device based on the relative locations of real objects present in the station keeping images; and output images depicting the virtual objects at positions on the screen to depict the virtual objects in the physical environment at the anchor locations.

Abstract: Embodiments provide for tracking location and resolving drift in Augmented Reality (AR) devices. The AR devices includes computing devices having screens on a first face and cameras on a second, opposite face to project an image onto optical arrangements for viewing by wearers of the AR devices. The AR devices map locations for real objects in the environment to a virtual environment; anchor virtual objects at anchor locations within the virtual environment; capture station keeping images of the environment from a first Field of View via the camera; determine a second, different Field of View in the environment for the wearer of the AR device based on the relative locations of real objects present in the station keeping images; and output images depicting the virtual objects at positions on the screen to depict the virtual objects in the physical environment at the anchor locations.

Abstract: Techniques for aligning a virtual object with a physical object in an Augmented Reality (AR) or Virtual Reality (VR) application are described. An electronic peripheral includes a first inertial measurement unit (“IMU”). A head mounted display includes a second IMU. An estimated attitude for the electronic peripheral is generated using data from the first IMU. An estimated attitude for the head mounted display is generated using data from the second IMU. An orientation of a virtual object is determined based on the estimated first and second attitudes, such that the virtual object is aligned with an object in a user's physical environment when the virtual object is displayed to the user. The virtual object is displayed on the head mounted display.

Abstract: The invention relates to members of the Fc receptor homolog (FcRH) subfamily, as well as fragments and variants thereof. Each FcRH is a Type I transmembrane receptor, preferably, comprises an extracellular region, a transmembrane region, and a cytoplasmic region. The cytoplasmic region preferably comprises one or more immunoreceptor tyrosine-based inhibitory or activation motifs (“ITIMs” or “ITAMs). The invention provides polypeptides, nucleic acids, vectors, expression systems, and antibodies and antibody fragments related to the FcRHs as well as uses thereof. Such uses include uses in the diagnosis and treatment of a malignancy of hematopoietic cell lineage or an inflammatory or autoimmune disease in a subject and in the modulation of a humoral immune response in a subject.

Abstract: Provided herein are antibodies having the same epitope specificity as an antibody produced by the hybridoma cell line deposited with the American Type Culture Collection as hybridoma 4-2A6, 1-5A3, or 1-3B4. Further provided herein are methods of identifying and selecting cells that express FcRH1 or FcRH4. Methods of diagnosing and treating a subject with a malignancy of a hematopoietic cell lineage or an autoimmune disease and methods of modulating a humoral immune response in a subject are also provided herein. Further provided herein are polypeptides comprising one or more complementary determining regions of the disclosed antibodies and nucleic acids that encode the disclosed polypeptides.

Abstract: Provided are methods of diagnosing in a subject a type of B-cell chronic lymphocytic leukemia (B-CLL). Also provided are antibodies, including monoclonal antibodies, that specifically bind FCRL2, FCRL3 or FCRL5 and methods of treating B-CLL using the antibodies.

Abstract: Provided herein are antibodies having the same epitope specificity as an antibody produced by the hybridoma cell line deposited with the American Type Culture Collection as hybridoma 4-2A6, 1-5A3, or 1-3B4. Further provided herein are methods of identifying and selecting cells that express FcRH1 or FcRH4. Methods of diagnosing and treating a subject with a malignancy of a hematopoietic cell lineage or an autoimmune disease and methods of modulating a humoral immune response in a subject are also provided herein. Further provided herein are polypeptides comprising one or more complementary determining regions of the disclosed antibodies and nucleic acids that encode the disclosed polypeptides.

Abstract: The invention relates to members of the Fc receptor homolog (FcRH) subfamily, as well as fragments and variants thereof. Each FcRH is a Type I transmembrane receptor, preferably, comprises an extracellular region, a transmembrane region, and a cytoplasmic region. The cytoplasmic region preferably comprises one or more immunoreceptor tyrosine-based inhibitory or activation motifs (“ITIMs” or “ITAMs). The invention provides polypeptides, nucleic acids, vectors, expression systems, and antibodies and antibody fragments related to the FcRHs as well as uses thereof. Such uses include uses in the diagnosis and treatment of a malignancy of hematopoietic cell lineage or an inflammatory or autoimmune disease in a subject and in the modulation of a humoral immune response in a subject.